The binding of aflatoxin B1, AFB1, a potent hepatocarcinogen, to various high molecular weight (HMW) DNAs from human normal liver and two liver cancer cell lines, Alexander primary liver carcinoma (PLC) and Mahlavu hepatocellular carcinoma (hHC) and from NIH/3T3 cell have been investigated. The kinetics of AFB1 binding to these DNAs showed similar initial rates but the extents of binding to the PLC and hHC DNAs seemed to be slightly higher. Preferential AFB1 bindings were identified in both PLC and hHC DNAs compared to normal liver DNA when analyzed by restriction endonuclease digestions and agarose gel electrophoresis. A critical AFB1 binding dosage, ranging 100 to 460 fmole/,Lg DNA, was found to activate the carcinogenic effect of the Mahlavu hHC HMW DNA, but not normal liver HMW DNA, rendering it capable of inducing focal transformation in NIH/3T3 cell. Excessive AFB1 binding on the hHC and PLC HMW DNAs resulted in an "over-kill" of both cell transformation capability and templating activity of the DNA.
Introduction
The highly carcinogenic agents are frequently also potent mutagens (1) . Their insults are often directed at macromolecules such as DNA generating modifications by way of chemical interactions that result in lethal lesions or codon alteration(s) similar to (point) mutations. Aflatoxin B1 (AFB1), a metabolite of Aspergillus flavus, is well known for its potency in hepatocarcinogenesis in numerous animal species including trout, rat, hamster, dog, and rhesus monkey (2) . AFB1 has also been implicated in the etiology of human liver cancer on the basis of significant statistical correlations between the increased occurrence of liver cancer in areas of Asia and Africa and the consumption of grains contaminated with AFB1 (3) (4) (5) . Furthermore AFB1 was reportedly detected in human liver cancer tissue samples (5, 6) . In the experimental animal, AFB1 was found to be activated by microsomal mixed-function oxidases in liver cells to form AFB,-2,3-epoxide (7) , which then *Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD bound to the N7 of guanine in both DNA and RNA leading to adduct formation (7, 8) . More recently, it has been reported that by using monoclonal antibody specific against AFB1-DNA adduct, AFB1-DNA adducts were detected in human urine samples and in liver biopsy samples obtained from patients (9) . In fibroblast tissue culture AFB1 has to be activated before it can act as a tumor initiator in conjunction with TPA, the tumor promotor, and is known to induce mutation in Chinese hamster cells and transform C3H/1OT1/2 mouse fibroblasts (10) . The ability of AFB1 to react with the cell's DNA in adduct formation thus depends on the activation of AFB1 to its reactive form by the cellular microsomal peroxidase such as in the liver cell. In order to understand the molecular mechanism in which AFB1 induces the process of hepatocarcinogenesis, it requires precise analysis on the binding affinity of AFB, with human liver DNA, the possibility of preferential targets within the genomic DNA as well as the genomic nature of the targeted DNA. In 
DNA Preparation and AFB1 Binding Reaction
Total and high molecular weight DNA was prepared from fresh liver tissue, minced and homogenized, or from frozen liver after pulverization in liquid N2 or from tissue culture cells in lysing buffer containing proteinase K (final concentration, 75 ,ug/mL), 50 mM Tris-HCI, pH 8.1, 1 mM EDTA, and 1% SDS, at 37°C for 2 hr as described earlier (11) . The preparations were then purified by sequential phenol-cresol, chloroform-isoamyl alcohol, and ether extractions followed by ethanol-NaCl precipitation at -20°C overnight. The DNA samples were then further purified by RNase digestion followed by a second sequence of phenol-cresol, chloroform-isoamyl alcohol, and ether extractions and ethanol-NaCl precipitation. When needed, the DNA samples were further banded by cesium chloride gradient centrifugation at 50,000 rpm for 18 hrs. The DNA samples were then dialyzed against Tris-HCl, 20 trophoresis. Agarose gel electrophoresis was carried out with 1% agarose at 50 V for 6 hr as described (11) . The gel was scanned for relative DNA concentration by absorbency at 260 m,u. It was then fractionated into 40 to 50 samples and the radioactivity determined. In some experiments the agarose gel was treated in Enhance (New England Nuclear, Boston, MA), rehydrated, dried, and fluorography taken. Recovery of DNA from agarose gel was carried out by electroelution (11) .
Cell-Transformation Assay by DNA Transfection
Transfection of NIH/3T3 cells with purified HMW DNA was carried out as described elsewhere (13 (11) . Filter hybridization was carried out as described earlier (11) (Fig. 3) . These critical doses range from 100 to 460 fmole/pug HMW DNA. In contrast, AFB1 binding did not render the HMW DNA from the other sources (NAL and NIH/3T3) capable of cell transformation. The addition of TPA to the transfected NIH/3T3 cultures did not increase the number of transformed foci in the assay (Table 1) . On the other hand, it seemed to augment the carcinogenic effect of the mutagenic AFB1 bound hHC DNA in the transfection assay. Focal transformation appeared earlier by 2 to 3 days in the presence of TPA, and the foci appeared larger and more prominent. Similar to observations reported elsewhere (10, 16) , TPA was thus considered a promotor and not an initiator in this study.
The transformed cells were successfully cloned by penny-cylinder, and DNA was extracted from the transfected clones for verifying the integration of the hHC AFB1-DNA in the mouse cell's genome. Figure 4 (Fig. 3) . In the four samples with binding of AFB1 at 520, 745, 1550, and 1600 fmole/,ug of HMW hHC DNA, no transformed foci were observed, although human HMW DNA was apparently detectable in these cultures when examined by DNA-DNA hybridization analysis as discussed above (Fig. 4) . When the biochemical parameter of templating capability of the DNAs bound with AFB1 at varying doses was examined, an inverse relationship seemed to exist between increasing dosage of AFB1 bound and the templating activity of AFB1-DNA. Figure 6 (Fig. 3) . It should be mentioned that, in the current study, total high molecular weight DNA (> 25 kb) was used in all experiments; thus the optimal AFB1 binding dosage may be much higher than the optimal dosage required for a molecularly cloned proto-oncogene of molecular size of a few kilobase pairs. It will be especially meaningful to determine the optimal dosage necessary for AFB1 activation of a human protooncogene with a known molecular size.
Excessive binding by [3H]AFBI on Mahlavu HMW
hHC DNA not only failed to activate the proto-oncogene but also diminished the template capability of the HMW DNA. In short an "overkill" effect in both DNA-mediated cell transformation and DNA templating capability was seen with excessive binding of AFB1 on HMW DNA.
It has been well documented that aflatoxin B1 is a potent hepatocarcinogen (1, 3, 4) . Its mechanism of action has yet to be well understood. Our current study and others suggested that one possible mode of aflatoxin B1 action resides in its affinity to form covalent linkage with the N7 of guanine in high molecular weight DNA. As established a Nar I restriction endonuclease site reading GCCGGC. The Nar I restriction endonuclease recognition sequence has been considered a diagnostic sequence for the 12th amino acid (GGC), glycine, of the n-ras oncogene family (20) . In bladder carcinoma such a sequence has been mutated to GCCGTC, and thus the 12th amino acid was replaced by valine (GTC) (20) . In our nucleotide sequence analysis, as well as suggested by others (18) , AFB1 shows high affinity with the second G in a tetranucleotide of CGGC. AFB1 bound to the N7 of guanine was reported to render the AFB,-G incapable of base-pairing with C but rather mispairing with A thus resulting in a (G-C to A-T) transversion type of mutation (21) . Whether a similar event has occurred in the HMW DNA of Mahlavu hepatocellular carcinoma cell upon AFB, binding at optimal concentration, awaits further detailed nucleotide sequence analysis.
